EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ethanol Ablation of Metastatic Lymph Nodes in Patients With Papillary Thyroid Carcinoma—Predictors of Clinical Outcome

Pål Stefan Frich iD, Eva Sigstad iD, Audun Elnæs Berstad iD, Else Marie Opsahl, Kristin Holgersen Fagerlid iD, Krystyna Kotanska Grøholt iD, Trine Bjøro iD, Knut Håkon Hole iD, Liv Ingrid Flinder iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Pål Stefan Frich und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiology and Nuclear Medicine, Department of Radiology, The Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Cancer, Papillary, Ethanol, Ablation Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ødegaard and Frimann-Dahls.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Ethanol ablation (EA) is a treatment option in recurrent or persistent metastatic lymph nodes (MLNs) from papillary thyroid carcinoma.

Objective

This work aimed to assess whether ultrasonographic characteristics of the MLN, history of lymph node surgery, aggressive histological subtype, or BRAFV600E mutation in the primary tumor predict long-term response from EA.

Methods

Seventy-five patients who received EA at a tertiary referral center were included. We evaluated treatment response from the most recent clinically indicated examination, or a study-specific examination. BRAFV600E analysis and review of histological subtypes in the primary tumor were conducted.

Results

Median interval from initial surgery to follow-up was 119 months (range, 39-471 months). Pure cystic MLN had a better outcome than the solid and partially cystic MLN (13/13, 100% vs 90/121, 74%; P = .039). Small MLNs (≤0.5 mL) had a higher response rate compared to larger lesions (71/92, 77% vs 10/19, 53%; P = .045). We observed no difference in EA response between patients with or without the BRAFV600E mutation (80/99, 81% vs 17/25, 68%; P = .181) or an aggressive subtype (22/24, 92% vs 75/100, 75%; P = .099) in their primary tumors. EA achieved similar rates of locoregional disease control in neck regions with or without previous lymph node surgery (66% vs 63%, P = .825).

Conclusion

EA was highly effective in pure cystic MLNs. Partially cystic or noncystic MLNs over 0.5 mL were less responsive, though many of these MLNs still showed a lasting response. BRAFV600E mutation, aggressive histological subtype, or absence of prior lymph node surgery did not negatively affect EA response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyroid Cancer, PapillaryEthanolAblation TechniquesHumansFemaleMaleMiddle AgedLymphatic MetastasisAdultProto-Oncogene Proteins B-rafAgedTreatment OutcomeLymph NodesYoung AdultRetrospective StudiesPrognosisMutationFollow-Up Studies

Stichwörter der Autor:innen

BRAF V600Eethanol ablationlymph node metastasispapillary thyroid carcinomatreatment response predictionultrasound-guided therapy

Substanzen

EthanolProto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Division of Radiology and Nuclear Medicine, Department of Radiology, The Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway.
  • Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway.
  • Division of Laboratory Medicine, Department of Pathology, Oslo University Hospital, 0424 Oslo, Norway.
  • Division of Cancer Medicine, Department of Surgical Oncology, Section of Breast- and Endocrine Surgery, Oslo University Hospital, 0424 Oslo, Norway.

ORCID-Profile: Pål Stefan Frich, Eva Sigstad, Audun Elnæs Berstad, Kristin Holgersen Fagerlid, Krystyna Kotanska Grøholt, Trine Bjøro, Knut Håkon Hole, Liv Ingrid Flinder

Förderung

  • Ødegaard and Frimann-Dahls

Zitieren

APA

Frich, P. S., Sigstad, E., Berstad, A. E., Opsahl, E. M., Fagerlid, K. H., Grøholt, K. K., Bjøro, T., Hole, K. H., & Flinder, L. I. (2025). Ethanol Ablation of Metastatic Lymph Nodes in Patients With Papillary Thyroid Carcinoma—Predictors of Clinical Outcome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf298

Vancouver

Frich PS, Sigstad E, Berstad AE, Opsahl EM, Fagerlid KH, Grøholt KK, et al. Ethanol Ablation of Metastatic Lymph Nodes in Patients With Papillary Thyroid Carcinoma—Predictors of Clinical Outcome. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf298

BibTeX
@article{Frich2025,
  author = {Frich, Pål Stefan and Sigstad, Eva and Berstad, Audun Elnæs and Opsahl, Else Marie and Fagerlid, Kristin Holgersen and Grøholt, Krystyna Kotanska and Bjøro, Trine and Hole, Knut Håkon and Flinder, Liv Ingrid},
  title = {Ethanol Ablation of Metastatic Lymph Nodes in Patients With Papillary Thyroid Carcinoma—Predictors of Clinical Outcome},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf298}
}
Kostenlos starten →